|
Nasdaq:IMGN
ImmunoGen,
Inc. is a developer of antibody-based cancer therapeutics. Its proprietary,
tumor-activated prodrug (TAP) technology combines extremely potent, small-molecule
drugs with monoclonal antibodies that recognize and bind specifically to
tumor cells
128 Sidney Street Cambridge,
MA 02139
Phone: (617) 995-2500 Fax:
(617) 995-2510
|
